stoxline Quote Chart Rank Option Currency Glossary
SciSparc Ltd. (SPRC)
3.8601  0.12 (3.21%)    02-27 14:29
Open: 3.94
High: 4.2861
Volume: 1,943,252
Pre. Close: 3.74
Low: 3.77
Market Cap: 2(M)
Technical analysis
2024-02-27 2:17:20 PM
Short term     
Mid term     
Targets 6-month :  6.37 1-year :  7.91
Resists First :  5.45 Second :  6.78
Pivot price 3.75
Supports First :  3.3 Second :  2.75
MAs MA(5) :  3.89 MA(20) :  3.73
MA(100) :  5 MA(250) :  9.35
MACD MACD :  -0.2 Signal :  -0.3
%K %D K(14,3) :  12.5 D(3) :  13.4
RSI RSI(14): 49.2
52-week High :  23.65 Low :  2.79
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ SPRC ] has closed below upper band by 28.0%. Bollinger Bands are 77.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 7 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 3.8 - 3.82 3.82 - 3.84
Low: 3.34 - 3.37 3.37 - 3.39
Close: 3.7 - 3.74 3.74 - 3.78
Company Description

SciSparc Ltd., a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. Its drug development programs include SCI-110 for the treatment of Tourette syndrome, obstructive sleep apnea, and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of autism spectrum disorder and epilepsy. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and CannAmide, a palmitoylethanolamide oral tablet in soft gel capsule form. It also has an agreement with the Sheba Fund for Health Services and Research to examine the potential role of SCI-210 for the treatment of status epilepticus; and The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel.

Headline News

Tue, 27 Feb 2024
Do Traders Think Scisparc Ltd (SPRC) Can Keep Climbing Tuesday? - InvestorsObserver

Tue, 27 Feb 2024
SciSparc gains as Clearmind partnership yields 3 new international patent applications - Seeking Alpha

Tue, 27 Feb 2024
SciSparc and Clearmind file new patent applications By - Canada

Tue, 27 Feb 2024
SciSparc-Clearmind Partnership Yields Three New International Patent Applications for MDMA, Ibogaine and Ketamine ... - TradingView

Fri, 23 Feb 2024
Can Scisparc Ltd (SPRC) Stock Rise to the Top of Healthcare Sector Friday? - InvestorsObserver

Wed, 13 Dec 2023
SciSparc Announces Positive Results for MitoCareX Bio with its Drug Discovery Platform - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 1 (M)
Shares Float 0 (M)
Held by Insiders 0 (%)
Held by Institutions 1 (%)
Shares Short 28 (K)
Shares Short P.Month 38 (K)
Stock Financials
EPS 919.88
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 14.47
Profit Margin 8.6 %
Operating Margin -150.5 %
Return on Assets (ttm) -33.2 %
Return on Equity (ttm) 4.7 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 6.33
EBITDA (p.s.) -11.48
Qtrly Earnings Growth 0 %
Operating Cash Flow -9 (M)
Levered Free Cash Flow -17 (M)
Stock Valuations
PE Ratio 0
PEG Ratio 0
Price to Book value 0.27
Price to Sales 0.62
Price to Cash Flow -0.23
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android